Piperazine derivative

A technology of compounds and compositions, applied in the directions of drug combinations, urinary system diseases, organic active ingredients, etc.

Active Publication Date: 2018-03-27
ASTELLAS PHARMA INC
View PDF8 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, these drugs have known cholinergic side effects such as dysentery, abdominal pain, and sweating

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Piperazine derivative
  • Piperazine derivative
  • Piperazine derivative

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0454] Hereinafter, the production method of the compound of formula (I) is demonstrated in more detail based on an Example. It should be noted that the present invention is not limited to the compounds described in the following examples. In addition, the production method of the raw material compound is shown in the production example. In addition, the production method of the compound of formula (I) is not limited to the production method of the specific examples shown below, the compound of formula (I) can also be obtained by a combination of these production methods, or it will be obvious to those skilled in the art method to manufacture.

[0455] In addition, the following abbreviations may be used in the tables mentioned later.

[0456] PEx: production example number, Ex: example number, PSyn: production method of the production example compound (the number in the PSyn column indicates that the compound is produced by the same method as the compound having its number as...

manufacture example 1

[0464] Under nitrogen atmosphere, borane-N,N-diethylaniline complex (46.2g), (S)-5,5-diphenyl-2-methyl-3,4-propanol-1 ,3,2- A mixture of oxazaboridine (1 M in toluene, 5 mL) and tert-butyl methyl ether (250 mL) was heated to 35°C. Next, a solution of 2-chloro-1-(4-chloro-2-fluorophenyl)ethanone (51 g) in tert-butyl methyl ether (300 mL) was added dropwise at 40° C. over 2 hours. After completion of the dropwise addition, the mixture was stirred overnight while cooling to room temperature. The reaction mixture was ice-cooled, and methanol (150 mL) was added dropwise. Then, a mixture of concentrated hydrochloric acid (80 mL) and water (220 mL) was added dropwise, and stirred for 1 hour under ice-cooling. After liquid separation of the reaction mixture, the aqueous layer was extracted with tert-butyl methyl ether. The organic layers were combined, washed with saturated brine, and dried over anhydrous magnesium sulfate. The insoluble matter was filtered off, and the filtrate...

manufacture example 2

[0466] A mixture of (1S)-2-chloro-1-(4-chloro-2-fluorophenyl)ethanol (8g) and methanol (4mL) was ice-cold, and tetrahydro-2H-pyran-4-amine (20mL) was added and sodium hydroxide (1.7 g). The reaction mixture was stirred overnight at 60 °C.

[0467] After cooling the reaction mixture to room temperature, it was poured into water (320 mL), and stirred at room temperature for 1 hour. The generated solid was collected by filtration, and the obtained solid was dried at 50° C. under reduced pressure. The obtained solid was added to a mixed solution of hexane (160 mL) and diisopropyl ether (16 mL), stirred at 70° C. for 4 hours, and stirred overnight while cooling to room temperature. The solid was collected by filtration and dried under reduced pressure at 50°C, thus obtaining (1S)-1-(4-chloro-2-fluorophenyl)-2-(tetrahydro-2H-pyran) as a solid -4-ylamino)ethanol (7.90 g).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention provides a compound that can be used as an MC4 receptor agonist. The inventors study MC4 receptor agonists, and confirm that a piperazine derivative has an action, thereby perfecting the present invention. Specifically, this piperazine derivative has an MC4 receptor agonist action and can be used as an agent for the prevention and/or treatment of bladder and urinary tract diseases, especially underactive bladder, hypotonic bladder, noncontracting bladder, detrusor muscle hypoactivity, neurogenic bladder, urethral relaxation failure, detrusor-external sphincter incoordination, and dysuria in benign prostatic hyperplasia.

Description

technical field [0001] The present invention relates to having melanocortin 4 receptor (hereinafter referred to as MC 4 A piperazine derivative or a salt thereof that has an agonist effect and can be used as an active ingredient of a pharmaceutical composition, especially a pharmaceutical composition for the prevention or treatment of bladder and urinary system diseases. Background technique [0002] The important functions of the lower urinary tract are urine storage and urination, but these functions are regulated by the coordinated action of the bladder and urethra. That is, when storing urine, the smooth muscle of the bladder relaxes, and the smooth muscle of the urethra and the external urethral sphincter contract, whereby the state of high urethral resistance is maintained and continence is maintained. On the other hand, the smooth muscle of the bladder contracts during urination, and at the same time the smooth muscle of the urethra relaxes, and the contraction of th...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/14A61K31/496A61K31/501A61P13/10C07D403/06C07D403/14C07D405/14C07D409/14C07D417/14
CPCC07D401/14C07D405/14A61K31/496A61K31/501C07D403/14C07D409/14C07D417/14C07D403/06A61P13/02A61P13/10
Inventor 菅根隆史牧野拓也山下大辅米德康博田名部大辅三原久史朝井范夫袭田一彦清水乔史森友博幸菅泽形造前野恭一细贝直美
Owner ASTELLAS PHARMA INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products